Julius Wolff Institute, Charité - Universitätsmedizin Berlin, Germany; Berlin-Brandenburg Center for Regenerative Therapies, Charité - Universitätsmedizin Berlin, Germany.
Center for Musculoskeletal Surgery, Charité - Universitätsmedizin Berlin, Germany.
Bone. 2014 Feb;59:162-72. doi: 10.1016/j.bone.2013.11.005. Epub 2013 Nov 12.
Local infections arising from fracture fixation, defect reconstruction or joint replacement can cause extreme pain and impaired healing, lead to revision operations, prolong hospital stay and increase costs. Treatment options including prophylaxis are afforded by the use of grafts and biomaterials loaded with antibiotics. These can produce local therapeutic concentrations with a reduced systemic concentration and reduced systemic side-effects. Patient-specific loading of osteogenic graft materials with antibiotic could be an important option for orthopaedic surgeons. A local therapeutic concentration must be available for the desired duration and cytotoxic effects must be kept within an acceptable range. The present study investigates a simple and reliable mixing procedure that could be used for the perioperative combination of antibiotic powders and solutions with bone grafting materials. The potential influence of concentration and sampling regime on the release kinetics of gentamicin, tobramycin and vancomycin was studied over a period of 56days and potency and cytotoxicity were evaluated. In all treatment groups, gentamicin and tobramycin were completely released within 3days whilst vancomycin was released over a period of 14days. The results clearly show that the main parameter influencing release is the molecular weight of the drug. Growth of Staphylococcus aureus was inhibited in all 3 treatment groups for at least 3days. Cell viability and alkaline phosphatase activity of primary osteoblast-like cells were not significantly affected by the antibiotic concentrations obtained from the elution experiments. Bone grafting is an established component of surgery for bone defect filling and for biological stimulation of healing. Patient-specific enhancement of such procedures by incorporation of antibiotics for infection prevention or by addition of cytokines for promotion of impaired healing or for treatment of critical size defects will be a relevant issue in the future.
局部感染源于骨折固定、缺损重建或关节置换,可导致剧烈疼痛和愈合受损,引发翻修手术,延长住院时间并增加成本。通过使用载抗生素的移植物和生物材料,可以提供包括预防措施在内的治疗选择。这些治疗方法可以在降低全身浓度和减少全身副作用的情况下,产生局部治疗浓度。将抗生素加载到成骨移植物材料中,为骨科医生提供了一种重要的选择。必须在所需的时间内提供局部治疗浓度,并且细胞毒性作用必须保持在可接受的范围内。本研究调查了一种简单可靠的混合程序,可用于围手术期将抗生素粉末和溶液与骨移植材料结合使用。研究了浓度和采样方案对庆大霉素、妥布霉素和万古霉素释放动力学的潜在影响,研究时间为 56 天,并评估了效力和细胞毒性。在所有治疗组中,庆大霉素和妥布霉素在 3 天内完全释放,而万古霉素则在 14 天内释放。结果清楚地表明,影响释放的主要参数是药物的分子量。所有 3 个治疗组中的金黄色葡萄球菌生长至少被抑制了 3 天。洗脱实验中获得的抗生素浓度对原代成骨样细胞的细胞活力和碱性磷酸酶活性没有显著影响。骨移植是骨缺损填充和生物刺激愈合的手术的既定组成部分。通过将抗生素纳入预防感染,或通过添加细胞因子来促进愈合受损或治疗临界尺寸缺陷,对这些手术进行个体化增强,将成为未来的一个相关问题。